Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients

Figure 3 Proportions of patients exhibiting virological response (serum Hepatitis B virus DNA concentration < 10³ copies/mL) in the tenofovir disoproxil fumarate and lamivudine plus adefovir treatment groups. No significant difference was noted at 4 wk between the two groups (P > 0.05). The rate of undetectability was significantly greater in the tenofovir disoproxil fumarate (TDF) group than in the lamivudine plus adefovir (LAM plus ADV) group at 12, 24, 36, and 48 wk (P < 0.001). LAM: Lamivudine; ADV: Adefovir.